News
BAX
39.47
-0.45%
-0.18
Implied VOO Analyst Target Price: $515
NASDAQ · 4d ago
Weekly Report: what happened at BAX last week (0408-0412)?
Weekly Report · 5d ago
Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Baxter International has a Return On Capital Employed of 6.9%. The company under-performs the Medical Equipment industry average of 9.6%. Baxter International is reinvesting in its business but returns have been falling over the last five years. The company's sales haven't changed much in the last 12 months. It doesn't have the makings of a multi-bagger. Simply Wall St looks at Baxter International's return on capital employed to compare it to others.
Simply Wall St · 6d ago
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
NASDAQ · 04/12 15:00
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
NASDAQ · 04/12 12:29
May 31st Options Now Available For Baxter International (BAX)
NASDAQ · 04/11 14:42
Baxter expands portfolio with new injectable products in U.S.
Healthcare Baxter expands portfolio with new injectable products in U.S. Baxter International announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.s. The company is a subsidiary of Baxter International Inc. (NYSE:BAX)
Seeking Alpha · 04/11 13:09
BAXTER INTERNATIONAL INC: CONTINUED EXPANSION OF ITS PHARMACEUTICALS PORTFOLIO WITH FIVE INJECTABLE PRODUCT LAUNCHES IN U.S.
Reuters · 04/11 12:32
Baxter Expands Pharmaceuticals Portfolio With Five Injectable Products In U.S.
Benzinga · 04/11 12:32
Press Release: Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors on May 2, 2024. The company will host a conference call to discuss its first-quarter 2024 financial results. The conference call will be held on Thursday, April 10, 2024 at 7:30 a.m. Central Time.
Dow Jones · 04/10 20:20
Weekly Report: what happened at BAX last week (0401-0405)?
Weekly Report · 04/08 09:21
Assessing Baxter Intl: Insights From 4 Financial Analysts
4 analysts have expressed a variety of opinions on Baxter Intl over the past quarter. The average price target for the company is $46.75, with a 12-month target of $54.00. Baxter offers a range of medical instruments and supplies to caregivers. The company's revenue growth rate is higher than peers in the Health Care sector.
Benzinga · 04/03 16:00
Baxter International Price Target Raised to $44.00/Share From $41.00 by Citigroup
Dow Jones · 04/03 15:43
Baxter International Is Maintained at Neutral by Citigroup
Dow Jones · 04/03 15:43
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
NASDAQ · 04/02 16:08
Baxter’s Novum IQ Launch: A Hold Rating Amid Competitive Challenges and Market Opportunities
TipRanks · 04/02 09:27
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
TipRanks · 04/02 07:50
BUZZ-U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
Stronger-than-expected manufacturing data propped up Treasury yields and tempered expectations of a rate cut in June. The Dow Jones Industrial Average was down 0.75% in midday trading on Monday. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 17:47
Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System
FDA grants 510(k) clearance to Baxter's Novum IQ large volume infusion pump with Dose IQ Safety Software. The two pumps share a common user interface to associate a patient, medication, and pump. The software features a customizable drug library and dose error reduction system.
Benzinga · 04/01 16:38
Monday's ETF with Unusual Volume: IYH
NASDAQ · 04/01 16:24
More
Webull provides a variety of real-time BAX stock news. You can receive the latest news about Baxter Intl Inc through multiple platforms. This information may help you make smarter investment decisions.
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies and precision positioning devices. Its Pharmaceuticals segment includes specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Its Kidney Care segment includes chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies.